I love the challenges of working with technology and life sciences companies as they evolve from startups to public companies.
+1 703 456 8084 mballantyne@cooley.com
Mark Ballantyne focuses his practice on representing IPO ready and publicly traded life sciences and technology companies, as well as underwriters.
Download full bio
OnCore Biopharma Announces Merger Agreement with Tekmira Pharmaceuticals
Verrica Pharmaceuticals – $86 Million IPO
Translate Bio – $122 Million IPO
2U $119 Million Initial Public Offering
T2 Biosystems IPO
View all
Emerging Companies
Mergers & Acquisitions
Capital Markets
Venture Capital
Golfing
Traveling
University of Richmond School of LawJD, magna cum laude, Order of the Coif, McNeill Law Society, 2012
Wake Forest UniversityBA, 2008
Virginia
Cooley Advises Meredith on $3.5 Billion of Debt Financings February 5, 2018
Valeritas – $53 Million IPO April 7, 2017
ObsEva – $97 Million IPO February 16, 2017
+1 703 456 8084 office +1 703 456 8100 fax mballantyne@cooley.com
Reston Town Center11951 Freedom Drive14th FloorReston, VA 20190-5640